Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis
about
Endothelin, hypertension and chronic kidney disease: new insights.Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.Resistant hypertension workup and approach to treatmentAddition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis.Endothelin, kidney disease, and hypertension.Endothelin receptor antagonists as antihypertensives: the next frontier.Endothelin antagonists in hypertension and kidney disease.Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis.Microvascular endothelial dysfunction predicts the development of erectile dysfunction in men with coronary atherosclerosis without critical stenoses.Random forest fishing: a novel approach to identifying organic group of risk factors in genome-wide association studies.
P2860
Q34028803-7A27B449-7980-4C32-8830-BCD0B56B7030Q34157915-29232F0E-9CDD-4111-8E4B-58FBA452ADB7Q34460704-7841CDCC-8720-4457-88D7-C2AD537E5B34Q34726905-4C0AC076-1AC1-481F-BD5F-48A23471DA66Q35182125-35DA822F-576B-4A99-B6FD-4143CFA9BC26Q36509293-35B6B8B0-1006-43A4-A474-339238AC51B0Q37227727-953326E3-5BAD-4BC9-B668-E12F3FC675D7Q37244292-8F9C3337-0C12-40F9-9CD5-7DB27E94F2C6Q37511009-4A8CC0D5-E405-4187-B3B5-D46E34CBF657Q38052428-BB15FF51-9633-43FD-8A42-AAC5F485D960Q39106330-6418F3D4-BC7C-4F2F-97BD-F91956C8EF13Q40493852-44E40715-390D-45F5-9BDD-95B1A3F16BCDQ41832833-E503FA3B-6CDD-4F4E-A4B9-A8ED4D56EFC6Q41878848-B65AB411-5A14-43FE-BC15-3ECEB5C3BCDC
P2860
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of atrasen ...... risk and early atherosclerosis
@en
Efficacy and safety of atrasen ...... isk and early atherosclerosis.
@nl
type
label
Efficacy and safety of atrasen ...... risk and early atherosclerosis
@en
Efficacy and safety of atrasen ...... isk and early atherosclerosis.
@nl
prefLabel
Efficacy and safety of atrasen ...... risk and early atherosclerosis
@en
Efficacy and safety of atrasen ...... isk and early atherosclerosis.
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of atrasen ...... risk and early atherosclerosis
@en
P2093
Abhiram Prasad
Bailey Kent
David R Holmes
Eugenia Raichlin
Geralyn M Pumper
Rebecca E Nelson
Verghese Mathew
P2860
P304
P356
10.1161/HYPERTENSIONAHA.108.113068
P407
P577
2008-08-11T00:00:00Z